Q2 revenue rose 5% to $16.6B, led by oncology and new launches, with strong progress in pipeline de-risking and regulatory milestones. Guidance for 2026 was raised, with EPS expected at $2.66–$2.76, including a major one-time charge. Confidence in long-term growth remains high.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.